trending Market Intelligence /marketintelligence/en/news-insights/trending/dgy96s7WowE7oCnW-Mu7KA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In this list

BioTime closes acquisition of Asterias Biotherapeutics

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

BioTime closes acquisition of Asterias Biotherapeutics

Alameda, Calif.-based BioTime Inc. completed its acquisition of biotechnology company Asterias Biotherapeutics Inc.

Under the all-stock deal, Asterias shareholders received 0.71 share of BioTime for each Asterias share held. Asterias owns about 16.2% of the combined company.

Asterias Biotherapeutics has filed for the delisting of its common shares on NYSE American following completion of the deal.

Fremont, Calif.-based Asterias develops cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer.